This year, Fox Chase Faculty and Fellows presented research that revealed tangible benefits for genitourinary cancer patient outcomes and quality of life.

Further Promise for Muscle-Invasive Bladder Cancer Patients in RETAIN-2 Trial

Building on the groundwork of RETAIN-1, the RETAIN-2 trial suggests that treating patients with neoadjuvant chemo-immunotherapy may be more effective than chemotherapy alone in eradicating the cancer and helping patients keep their bladders. Pooja Ghatalia, MD, Associate Professor, Department of Hematology/Oncology, presented the encouraging results. Read More.

Positive News for Kidney Cancer Patients Who Have a Good Response to Combination Therapy

A Fox Chase Cancer Center study has demonstrated that some patients with metastatic kidney cancer receiving combination therapy can safely stop or pause treatment after two years, if they have a good response. Lead author Matthew R. Zibelman, MD, Associate Professor, Department of Hematology/Oncology, noted that investigating this combination therapeutic approach as a prospective approach is a first. Read More.

Trending: Number of GEC Patients Treated with Immune Checkpoint Inhibitors Increases

Jasmeet Kaur, MBBS, MD, a second-year Fellow in the Department of Hematology/Oncology at Fox Chase, was the lead author in a compelling Fox Chase study that found the number of patients with gastroesophageal cancer (GEC) who received immune checkpoint inhibitors and had PD-L1 testing increased significantly between 2011 and 2021. Read More.